Newsroom | 4690 results

ARLINGTON, Virginia & REYKJAVIK, Iceland--(BUSINESS WIRE)--Kerecis launches Compact, a compressed disc fish-skin graft designed to reduce waste, improve handling, and treat deep, complex wound defects....

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the Company will report clinical data from the Phase 1 study evaluating prulacabtagene leucel (prula-cel) as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephritis...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and Seoul National University Hospital (SNUH), a leading translational medical center in South Korea, today announced a partnership to evaluate automated manufacturing for a gene-modified hematopoietic stem and progenitor cell (HSPC) therapy targeting paroxysmal nocturnal hemoglobinuria (PNH) on Cellares’ Cell Shuttle platform. The collaboration will evaluate the trans...

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the completion of patient enrollment in the U.S. ASTRA Phase 3 pivotal study of AURN001, a single-administration investigational regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction. AURN001 has the potential to...

LOUISVILLE, Ky.--(BUSINESS WIRE)--XLerateHealth receives $2.5M NIH/NIGMS Phase IIB grant to scale its Commercialization Engine for universities, biotech hubs, health systems and ESOs....

SAN FRANCISCO & NEW YORK & MONTREAL--(BUSINESS WIRE)--Encellin, Inc., a clinical-stage biotechnology company developing Encapsulated Cell Replacement Therapy (ENCRT), today announced a partnership with Breakthrough T1D, the leading global Type 1 Diabetes (T1D) research and advocacy organization, and an award through its Industry Discovery and Development Partnership (IDDP) program to support the advancement of Encellin’s ENCRT-103-hPI clinical program in T1D. The new trial (NCT07680673) will br...

BLUE ASH, Ohio--(BUSINESS WIRE)--Resilience, a technology-forward contract development and manufacturing organization (CDMO) dedicated to broadening access to complex medicines, today announced that in line with its more focused operating model, the company has divested a non‑core asset to further streamline operations and strengthen long‑term value creation. The company’s cell therapy manufacturing facility in East Norriton, Pennsylvania was acquired by Made Scientific, Inc. “Over the past yea...

RESEARCH TRIANGLE PARK, N.C. & THE WOODLANDS, Texas--(BUSINESS WIRE)--Kincell Bio and Cellipont Bioservices today announced the completion of their merger to form Kincellis Advanced Therapies (Kincellis), a U.S.-based contract development and manufacturing organization focused on cell therapies and other advanced modalities. Kincellis Advanced Therapies brings together Kincell’s depth in immune-cell technologies with Cellipont’s experience across stem cells, iPSCs, MSCs, dendritic cells, exosom...

NEW YORK--(BUSINESS WIRE)--Polyphron, a company building artificial human biology to transform drug development and treat disease, announced $20M in seed financing led by Quiet Capital, with participation from Gradient, Haystack, and Compound. Polyphron trains frontier AI models to manufacture and simulate living tissue to create the verification substrate for AI-driven biology. AI systems are becoming increasingly capable of generating drug candidates, biological hypotheses, and experimental d...

MENLO PARK, Calif.--(BUSINESS WIRE)--Three-year data suggest improved overall survival with TREGZI™ versus post-transplant cyclophosphamide in patients with hematologic malignancies....